We are live on ! Find out more
ORIC icon

Oric Pharmaceuticals
ORIC

101 hedge funds and large institutions have $182M invested in Oric Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 22 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 12

26% more funds holding

Funds holding: 80 → 101 (+21)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2.24% less ownership

Funds ownership: 88.52% → 86.27% (-2.2%)

21% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 28

65% less capital invested

Capital invested by funds: $512M → $182M (-$330M)

Holders
101
Holders Change
+21
Holders Change %
+26.25%
% of All Funds
1.59%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
33
Increased
22
Reduced
28
Closed
12
Calls
$1.1M
Puts
–
Net Calls
+$1.1M
Net Calls Change
+$1.1M

Top Buyers

1
First Manhattan
First Manhattan
New York
+$17.6M
2
BC
Boxer Capital
California
+$7.69M
3
Alkeon Capital Management
Alkeon Capital Management
New York
+$4.32M
4
Millennium Management
Millennium Management
New York
+$3.4M
5
Two Sigma Investments
Two Sigma Investments
New York
+$2.88M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$15.8M
2
Jennison Associates
Jennison Associates
New York
-$14.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.4M
4
State Street
State Street
Massachusetts
-$6.11M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$5.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$1.15M -$80.3K -8,918 -4%
Wells Fargo
27
Wells Fargo
California
$953K -$34.5K -3,834 -2%
IBT
28
International Biotechnology Trust
United Kingdom
$905K +$209K +23,217 +15%
ROTUOC
29
Regents of the University of California
California
$792K – – –
N
30
Nuveen
North Carolina
$753K +$14.3K +1,589 +1%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$590K -$20.3K -2,249 -2%
State of Wisconsin Investment Board
32
State of Wisconsin Investment Board
Wisconsin
$586K +$645K +71,600 +187%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$574K +$968K +107,500 New
PP
34
PDT Partners
New York
$421K +$412K +45,763 +138%
CSS
35
Cubist Systematic Strategies
Connecticut
$404K +$681K +75,599 New
GCM
36
Graham Capital Management
Connecticut
$394K +$666K +73,919 New
Morgan Stanley
37
Morgan Stanley
New York
$391K +$242K +26,830 +58%
AC
38
Aristides Capital
Kentucky
$374K +$630K +70,000 New
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$340K +$143K +15,891 +33%
Swiss National Bank
40
Swiss National Bank
Switzerland
$324K +$38.7K +4,300 +8%
Goldman Sachs
41
Goldman Sachs
New York
$322K +$148K +16,391 +37%
TI
42
Trexquant Investment
Connecticut
$287K +$484K +53,760 New
HF
43
HRT Financial
New York
$248K +$418K +46,446 New
GCP
44
GSA Capital Partners
United Kingdom
$227K +$167K +18,553 +77%
JF
45
Jump Financial
Illinois
$213K +$360K +40,000 New
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$208K +$26.3K +2,921 +8%
OQS
47
Occudo Quantitative Strategies
Florida
$198K +$333K +36,991 New
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$192K -$22.2K -2,460 -6%
Los Angeles Capital Management
49
Los Angeles Capital Management
California
$191K +$139K +15,450 +76%
AllianceBernstein
50
AllianceBernstein
Tennessee
$177K +$901 +100 +0.3%
1
2
3 4 5

ORIC Hedge Fund Activity: Q1 2022 in Review

101 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2022, worth a combined $182M — down 65% from $512M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ORIC positions and 12 closed out — a net gain of 21 holders — while 22 added to existing stakes and 28 trimmed.

The largest buyer was First Manhattan, opening a new position worth an estimated $17.6M. The largest seller was Victory Capital Management, cutting an estimated $15.8M.

  • 101 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2022, up from 80 in Q4 2021.
  • Funds reported $182M of Oric Pharmaceuticals stock for Q1 2022, down 65% quarter-over-quarter.
  • 33 funds opened new Oric Pharmaceuticals positions in Q1 2022 and 12 closed out, a net change of +21 holders.
  • The largest Oric Pharmaceuticals buyer in Q1 2022 was First Manhattan, an estimated $17.6M added.
  • The largest Oric Pharmaceuticals seller in Q1 2022 was Victory Capital Management, an estimated $15.8M sold.

Based on aggregated 13F filings for Q1 2022.